Concord Biotech Limited vs GlaxoSmithKline Pharmaceuticals Limited
Last updated: 22 October 2026
Concord Biotech vs GlaxoSmithKline Pharma: A MoneyDock Comparison
Concord Biotech Limited and GlaxoSmithKline Pharmaceuticals Limited are two prominent players in the Indian pharmaceutical sector, offering distinct profiles for investors. Concord Biotech is known for its research and development driven approach, focusing on fermentation-based biopharmaceutical products. GlaxoSmithKline Pharma, on the other hand, is a well-established multinational pharmaceutical company with a broad portfolio of prescription medicines and vaccines. This comparison aims to provide a data-driven overview of their current market performance and financial standing, assisting MoneyDock readers in making informed investment decisions based on the provided metrics.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | GlaxoSmithKline Pharmaceuticals Limited |
|---|---|---|
| Current Price | ₹1270.70 | ₹2433.70 |
| 52-Week High | ₹1579.40 | ₹3106.40 |
| 52-Week Low | ₹1014.80 | ₹2103.20 |
| 1-Year Return | -7.88% | -5.87% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Based on the provided numbers, a direct valuation comparison using the Trailing P/E ratio and Market Cap is not possible as both are listed as 'N/A' for both companies. This limits our ability to gauge their current valuation relative to earnings or overall size within the market.
When it comes to returns, neither company has delivered positive results over the past year. GlaxoSmithKline Pharmaceuticals Limited shows a slightly better performance with a 1-Year Return of -5.87% compared to Concord Biotech Limited's -7.88%. This suggests that GlaxoSmithKline has experienced less of a downturn in the last twelve months, indicating a marginal edge in recent performance stability.
Examining price stability through the lens of 52-week highs and lows, Concord Biotech's current price of ₹1270.70 is closer to its 52-week low of ₹1014.80 than its high of ₹1579.40. This places it approximately 20% above its 52-week low. GlaxoSmithKline, with a current price of ₹2433.70, is also closer to its 52-week low of ₹2103.20 than its high of ₹3106.40, being about 15% above its 52-week low. Both stocks are currently trading closer to their respective 52-week lows, which could suggest potential for rebound or continued pressure, depending on underlying factors not provided here. However, without P/E and Market Cap data, a deeper analysis into their fundamental stability remains limited.
MoneyDock Verdict
For Aggressive Investors: With both companies showing negative 1-year returns and trading closer to their 52-week lows, aggressive investors might see this as an opportunity for turnaround plays. GlaxoSmithKline's slightly smaller negative return might suggest marginally better resilience. However, the lack of P/E and Market Cap data means investing would require significant further research beyond these metrics.
For Conservative Investors: The absence of Trailing P/E and Market Cap data, combined with negative 1-year returns for both stocks, makes it challenging to assess their fundamental value and stability accurately. Conservative investors typically prefer stocks with clearer valuation metrics and more stable or positive returns. Based solely on the given data, both present a higher degree of uncertainty, making them less suitable for a purely conservative approach without more detailed financial analysis.
For Long-Term SIP Investors: For long-term SIP investors, both stocks are in a downtrend based on 1-year returns. GlaxoSmithKline's performance is marginally better. The current prices being closer to 52-week lows could potentially offer a 'buy the dip' scenario for those with high conviction in the long-term prospects of either company's business model. However, without crucial valuation metrics like P/E and Market Cap, it's hard to ascertain if current prices represent true value for long-term accumulation.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.